CN102858159B - 化合物 - Google Patents
化合物 Download PDFInfo
- Publication number
- CN102858159B CN102858159B CN201180021342.6A CN201180021342A CN102858159B CN 102858159 B CN102858159 B CN 102858159B CN 201180021342 A CN201180021342 A CN 201180021342A CN 102858159 B CN102858159 B CN 102858159B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- methoxy
- mmol
- ethyl
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCC[C@](CC)(C1)N[C@](c2ccccc2)c(cc(c(C(NC(C*)C*)=O)c2)OC)c2S1(=O)=O Chemical compound CCCC[C@](CC)(C1)N[C@](c2ccccc2)c(cc(c(C(NC(C*)C*)=O)c2)OC)c2S1(=O)=O 0.000 description 4
- IOGIXVPZTPHLGS-UHFFFAOYSA-O CCCCC(CC)(C1)NC(C2CCCCC2)C(CC(C(CC[PH2+]O)C2)OC)C2[S+]1O Chemical compound CCCCC(CC)(C1)NC(C2CCCCC2)C(CC(C(CC[PH2+]O)C2)OC)C2[S+]1O IOGIXVPZTPHLGS-UHFFFAOYSA-O 0.000 description 1
- MYJNGBRFGSCFCI-QTTOCAHCSA-N CCCCC(CC)(CC)N[C@H](C1C=SCCC1)C(CC1O)C(C)=CC1OC Chemical compound CCCCC(CC)(CC)N[C@H](C1C=SCCC1)C(CC1O)C(C)=CC1OC MYJNGBRFGSCFCI-QTTOCAHCSA-N 0.000 description 1
- NKAHCIQXTPXCPI-XZOQPEGZSA-O CCCC[C@](CC)(C1)N[C@@H](c2ccccc2)c2cc(OC)c(CP(O)(O)O)cc2[S+]1(O)=O Chemical compound CCCC[C@](CC)(C1)N[C@@H](c2ccccc2)c2cc(OC)c(CP(O)(O)O)cc2[S+]1(O)=O NKAHCIQXTPXCPI-XZOQPEGZSA-O 0.000 description 1
- VFWZVYNEFRPIBV-JWQCQUIFSA-N CCCC[C@](CC)(C1)N[C@H](C2=CC=CCC2)c(cc(c(CNC(CCl)=O)c2)OC)c2S1(=O)=O Chemical compound CCCC[C@](CC)(C1)N[C@H](C2=CC=CCC2)c(cc(c(CNC(CCl)=O)c2)OC)c2S1(=O)=O VFWZVYNEFRPIBV-JWQCQUIFSA-N 0.000 description 1
- DDVHNXVRSXXUKV-JWQCQUIFSA-N CCCC[C@](CC)(C1)N[C@H](c2ccccc2)c(cc(c(CCC)c2)OC)c2S1(=O)=O Chemical compound CCCC[C@](CC)(C1)N[C@H](c2ccccc2)c(cc(c(CCC)c2)OC)c2S1(=O)=O DDVHNXVRSXXUKV-JWQCQUIFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/6541—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32821210P | 2010-04-27 | 2010-04-27 | |
| US61/328,212 | 2010-04-27 | ||
| US61/328212 | 2010-04-27 | ||
| US32922510P | 2010-04-29 | 2010-04-29 | |
| US61/329,225 | 2010-04-29 | ||
| US61/329225 | 2010-04-29 | ||
| PCT/US2011/034024 WO2011137135A1 (en) | 2010-04-27 | 2011-04-27 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102858159A CN102858159A (zh) | 2013-01-02 |
| CN102858159B true CN102858159B (zh) | 2015-02-11 |
Family
ID=44861895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180021342.6A Active CN102858159B (zh) | 2010-04-27 | 2011-04-27 | 化合物 |
Country Status (39)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5889321B2 (ja) | 2010-11-04 | 2016-03-22 | アルビレオ アクチエボラグ | 肝疾患の処置用のｉｂａｔ阻害剤 |
| KR20140067070A (ko) | 2011-08-31 | 2014-06-03 | 말린크로트 엘엘씨 | Ｈ-포스포네이트에 의한 나노입자 ｐｅｇ 개질 |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| RU2015144632A (ru) | 2013-05-02 | 2017-06-07 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Терапевтические пептиды |
| JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Ｅａファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| EP3177600B1 (en) | 2014-08-05 | 2018-05-23 | Glaxosmithkline Intellectual Property (No. 2) Limited | Synthesis of benzothiazepines |
| KR101674806B1 (ko) * | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| AU2016215432B2 (en) | 2015-02-02 | 2020-07-30 | Valo Early Discovery, Inc. | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors |
| AR103598A1 (es) | 2015-02-02 | 2017-05-24 | Forma Therapeutics Inc | Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| AU2017286943B2 (en) | 2016-06-27 | 2019-05-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Synthetic methods |
| EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP3802504B1 (en) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2019245448A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Crystal modifications of odevixibat |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| RS63899B1 (sr) | 2019-02-06 | 2023-02-28 | Albireo Ab | Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| EP3921027B1 (en) | 2019-02-06 | 2023-07-19 | Albireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| PT3923943T (pt) | 2019-02-12 | 2024-10-23 | Mirum Pharmaceuticals Inc | Resposta dependente da dose e do genótipo a um asbti em doentes com deficiência na bomba de exportação de sais biliares |
| CN114761018B (zh) | 2019-12-04 | 2025-12-02 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| TWI871392B (zh) * | 2019-12-04 | 2025-02-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| TWI867107B (zh) * | 2019-12-04 | 2024-12-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
| MX2022006731A (es) * | 2019-12-04 | 2022-06-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar. |
| TWI865673B (zh) * | 2019-12-04 | 2024-12-11 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| AR120682A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar |
| EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023548788A (ja) | 2020-10-20 | 2023-11-21 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド | 胆汁うっ滞性そう痒症を治療する方法 |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| KR20230117393A (ko) | 2020-12-04 | 2023-08-08 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도 |
| CA3205558A1 (en) | 2020-12-23 | 2022-06-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Forms of linerixibat |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| JP2025516153A (ja) | 2022-04-22 | 2025-05-27 | アルビレオ・アクチボラグ | Ａｓｂｔ阻害剤の皮下投与 |
| US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
| JP2025521736A (ja) | 2022-07-05 | 2025-07-10 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| WO2024121434A1 (en) | 2022-12-09 | 2024-06-13 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
| WO2024251739A1 (en) | 2023-06-06 | 2024-12-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel use of an ileal bile acid transporter inhibitor for the treatment of pruritus |
| WO2025078973A1 (en) | 2023-10-09 | 2025-04-17 | Assia Chemical Industries Ltd. | Solid state forms of linerixibat and process for preparation thereof |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663165A (en) * | 1992-02-17 | 1997-09-02 | Glaxo Wellcome Inc. | Hypolipidaemic benzothiazepine compounds |
| CN1059673C (zh) * | 1994-08-10 | 2000-12-20 | 惠尔康基金会集团公司 | 降血脂1,4－苯并氮杂䓬－1,1－二氧化物 |
| US20030195218A1 (en) * | 2002-01-17 | 2003-10-16 | Pharmacia Corporation | Novel alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2370015A (en) | 1933-07-24 | 1945-02-20 | Merck & Co Inc | Derivatives of tertiary amino aliphatic acids |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| WO2002053548A1 (fr) | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Derives de la benzothiazepine |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20040077625A1 (en) * | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| JP2006517415A (ja) | 2003-01-09 | 2006-07-27 | ジェネンテック・インコーポレーテッド | ポリペプチドの精製 |
| GB0304194D0 (en) * | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| CA2583428A1 (en) | 2004-09-03 | 2006-03-09 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
| WO2010062861A2 (en) * | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
-
2011
- 2011-04-25 JO JOP/2011/0139A patent/JO3131B1/ar active
- 2011-04-26 UY UY0001033353A patent/UY33353A/es not_active Application Discontinuation
- 2011-04-26 AR ARP110101432A patent/AR081337A1/es active IP Right Grant
- 2011-04-27 RS RS20160709A patent/RS55079B1/sr unknown
- 2011-04-27 US US13/640,166 patent/US9040518B2/en active Active
- 2011-04-27 MY MYPI2012004753A patent/MY162933A/en unknown
- 2011-04-27 SI SI201130920A patent/SI2563122T1/sl unknown
- 2011-04-27 PH PH1/2012/502128A patent/PH12012502128B1/en unknown
- 2011-04-27 KR KR1020127030621A patent/KR101769079B1/ko active Active
- 2011-04-27 PE PE2012002082A patent/PE20130384A1/es active IP Right Grant
- 2011-04-27 PT PT117755132T patent/PT2563122T/pt unknown
- 2011-04-27 BR BR112012026767A patent/BR112012026767B1/pt active IP Right Grant
- 2011-04-27 DK DK11775513.2T patent/DK2563122T3/en active
- 2011-04-27 AU AU2011245393A patent/AU2011245393B2/en active Active
- 2011-04-27 LT LTEP11775513.2T patent/LT2563122T/lt unknown
- 2011-04-27 JP JP2013508174A patent/JP5702853B2/ja active Active
- 2011-04-27 NZ NZ602754A patent/NZ602754A/en unknown
- 2011-04-27 PL PL11775513.2T patent/PL2563122T3/pl unknown
- 2011-04-27 MA MA35373A patent/MA34235B1/fr unknown
- 2011-04-27 CA CA2795543A patent/CA2795543C/en active Active
- 2011-04-27 ME MEP-2016-160A patent/ME02490B/me unknown
- 2011-04-27 MX MX2012012527A patent/MX2012012527A/es active IP Right Grant
- 2011-04-27 SG SG2012074860A patent/SG184812A1/en unknown
- 2011-04-27 EP EP11775513.2A patent/EP2563122B1/en active Active
- 2011-04-27 HR HRP20161103TT patent/HRP20161103T1/hr unknown
- 2011-04-27 UA UAA201211711A patent/UA110338C2/ru unknown
- 2011-04-27 CN CN201180021342.6A patent/CN102858159B/zh active Active
- 2011-04-27 HU HUE11775513A patent/HUE029480T2/en unknown
- 2011-04-27 WO PCT/US2011/034024 patent/WO2011137135A1/en not_active Ceased
- 2011-04-27 ES ES11775513.2T patent/ES2588743T3/es active Active
- 2011-04-27 EA EA201290909A patent/EA021753B1/ru not_active IP Right Cessation
-
2012
- 2012-09-28 CO CO12170751A patent/CO6612267A2/es active IP Right Grant
- 2012-10-04 DO DO2012000263A patent/DOP2012000263A/es unknown
- 2012-10-11 IL IL222365A patent/IL222365A/en active IP Right Grant
- 2012-10-18 ZA ZA2012/07858A patent/ZA201207858B/en unknown
- 2012-10-26 CL CL2012003009A patent/CL2012003009A1/es unknown
- 2012-11-01 CR CR20120557A patent/CR20120557A/es unknown
-
2016
- 2016-08-24 CY CY20161100830T patent/CY1118187T1/el unknown
- 2016-08-29 SM SM201600293T patent/SMT201600293B/it unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663165A (en) * | 1992-02-17 | 1997-09-02 | Glaxo Wellcome Inc. | Hypolipidaemic benzothiazepine compounds |
| CN1059673C (zh) * | 1994-08-10 | 2000-12-20 | 惠尔康基金会集团公司 | 降血脂1,4－苯并氮杂䓬－1,1－二氧化物 |
| US20030195218A1 (en) * | 2002-01-17 | 2003-10-16 | Pharmacia Corporation | Novel alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102858159B (zh) | 化合物 | |
| AU2011245393A1 (en) | Chemical compounds | |
| CN104603127B (zh) | 补体途径调节剂及其应用 | |
| CN103097364B (zh) | 作为s1p调节剂的螺-哌啶衍生物 | |
| TW202227397A (zh) | 雙環的－雜環衍生物及相關用途 | |
| TW202200559A (zh) | Ｇｌｐ－１受體促效劑、包含該促效劑之醫藥組成物及其製備方法 | |
| CN116635393A (zh) | 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 | |
| CN101784535A (zh) | 作为s1p1受体激动剂的新的二羧酸衍生物 | |
| WO2016150255A1 (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
| TW201609634A (zh) | 吡咯啶基碸類視色素相關孤兒受體γ（ＲＯＲγ）調節劑 | |
| WO2024083256A1 (zh) | pan-KRAS降解剂及其制备方法和应用 | |
| WO2024088408A1 (zh) | 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用 | |
| CN109071548A (zh) | 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物 | |
| CN119110802A (zh) | 中环或大环苄基取代的杂环衍生物和相关用途 | |
| CN115867545A (zh) | 抗病毒素1,3-二氧代茚化合物 | |
| EP4486445A1 (en) | Bicyclic-heterocycle derivatives and related uses | |
| CN115209955A (zh) | 治疗家族性自主神经功能障碍的化合物 | |
| HK1175650B (en) | Chemical compounds | |
| TWI753550B (zh) | 經取代的1,3-苯基雜芳基衍生物及其在治療疾病中之用途 | |
| WO2025097835A1 (zh) | 一种glp-1r激动剂化合物及其应用 | |
| CN115677830A (zh) | 肽酰胺类化合物及其制备方法与应用 | |
| HK1226055B (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
| HK1176934B (en) | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes | |
| HK1176934A1 (zh) | 杂芳基-环己基-四氮杂苯并[e]薁 | |
| JP2003246787A (ja) | ディスコハブディン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |